The GABI-R addresses a lack of data about bioresorbable scaffolds in daily practice.
5000 patients with minimal in- and exclusion criteria at 100 sites will be enrolled.
A follow-up period of 5 years is planned.
Endpoints are cardiac death, myocardial infarction, target vessel and target lesion revascularization.
Symptoms, quality of life and economical aspects will be evaluated as well.